E
URGN icon

Ergoteles’s UroGen Pharma URGN Stock Holding History

Ergoteles’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-38,603
Closed -$342K – 1773
2022
Q4 		$342K Sell
38,603
-42,818
-53% -$406K 0.01% 863
2022
Q3 		$677K Sell
81,421
-1,694
-2% -$14K 0.02% 650
2022
Q2 		$681K Buy
+83,115
New +$571K 0.02% 704

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ergoteles's URGN Position: Q1 2023 in Review

Ergoteles sold out of UroGen Pharma (URGN) in Q1 2023, closing a stake of 38,603 shares — an estimated $342K sold.

Ergoteles first reported a position in URGN in Q2 2022 and held it in 3 quarters. The position peaked at $681K in Q2 2022. 65 funds tracked by Wall St. Rank hold URGN as of Q1 2023.

  • Ergoteles reported no remaining UroGen Pharma position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 38,603 UroGen Pharma shares in Q1 2023, an estimated $342K.
  • Ergoteles first reported a position in UroGen Pharma in Q2 2022 and held it in 3 quarters.
  • Ergoteles's UroGen Pharma position peaked at $681K in Q2 2022.
  • 65 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.